Optimal Immobilization of β-Galactosidase onto κ-Carrageenan Gel Beads Using Response Surface Methodology and Its Applications

Autor: Magdy M. Elnashar, Ghada E. Awad, Mohamed E. Hassan, Mohamed S. Mohy Eldin, Bakry M. Haroun, Ahmed I. El-Diwany

Publikováno v: The Scientific World Journal, Vol 2014 (2014)

β-Galactosidase (β-gal) was immobilized by covalent binding on novel κ-carrageenan gel beads activated by two-step method; the gel beads were soaked in polyethyleneimine followed by glutaraldehyde. 22 full-factorial central composite experiment de

Externí odkaz: https://doaj.org/article/5d9be3de5eda46a4a516743b9622cf7a

Carbohydrate microcapsules tailored and grafted for covalent immobilization of glucose isomerase for pharmaceutical and food industries

Autor: Mohamed E, Hassan, Ghada E A, Awad, Mohamed S, MohyEldin, Bakry M, Haroun, Ahmed I, El-Diwany, Magdy M, Elnashar

Publikováno v: Biotechnology letters.

Carrageenan is one of the most common carbohydrates utilised in the entrapment industry to immobilise cells and enzymes. However, it lacks functionality. Carrageenan has been grafted to produce fructose by covalently immobilising glucose isomerase (G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::99e8e08079ca3fa6dd02de3b84e23bef
https://pubmed.ncbi.nlm.nih.gov/36482052

Low-dose nano-gel incorporated with bile acids enhanced pharmacology of surgical implants.

Autor: Mooranian A; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia.; School of Pharmacy, University of Otago, Dunedin, Otago, New Zealand., Ionescu CM; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia., Wagle SR; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia., Kovacevic B; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia., Walker D; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia., Jones M; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia., Chester J; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia., Johnston E; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia., Mikov M; Department of Pharmacology, Toxicology & Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, 21101, Serbia., Stankov K; Department of Pharmacology, Toxicology & Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, 21101, Serbia., Elnashar M; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia., Al-Salami H; The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Western Australia, 6102, Australia.; Medical School, University of Western Australia, Perth, We--stern Australia, Australia.

Publikováno v: Therapeutic delivery [Ther Deliv] 2023 Jan; Vol. 14 (1), pp. 17-29. Date of Electronic Publication: 2023 Mar 15.

An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques.

Autor: Mooranian A; Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia., Zamani N; Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia., Takechi R; School of Public Health, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia., Luna G; Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia., Mikov M; Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia., Goločorbin-Kon S; Department of Pharmacy, University of Novi Sad, Novi Sad, Serbia., Elnashar M; Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia., Arfuso F; Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia., Al-Salami H; Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.

Publikováno v: PloS one [PLoS One] 2019 Apr 04; Vol. 14 (4), pp. e0214984. Date of Electronic Publication: 2019 Apr 04 (Print Publication: 2019).